Online inquiry

IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3472MR)

This product GTTS-WQ3472MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets pcrV gene. The antibody can be applied in Pseudomonas aeruginosa infections research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq WP_003100789.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
UniProt ID O30527
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3472MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14057MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-3918
GTTS-WQ7272MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FP3 protein
GTTS-WQ15739MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA VX-15
GTTS-WQ7655MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GEN-1029
GTTS-WQ15924MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ12669MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA OMP-18R5
GTTS-WQ6201MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CP-870893
GTTS-WQ8953MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IL2 fused to diphteria toxin
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW